Biomarkers to predict therapeutic response in chronic spontaneous urticaria: a review
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Identifying biomarkers for chronic spontaneous urticaria (CSU) treatment response is crucial. Current biomarkers show promise but require validation for personalized CSU therapy.
Area Of Science
- Dermatology and Immunology
- Pharmacogenomics and Personalized Medicine
Background
- Chronic spontaneous urticaria (CSU) is a mast cell-mediated disorder impacting quality of life, with variable response to treatments like antihistamines, omalizumab, and cyclosporine.
- Patient heterogeneity leads to uncontrolled or poorly controlled disease, necessitating personalized treatment strategies.
Approach
- Review and summarize existing research on biomarkers for predicting therapeutic response in CSU.
- Analyze the role of various biomarkers in predicting response to antihistamines, omalizumab, and cyclosporine.
Key Points
- Predictors of non-response to antihistamines include high disease activity, elevated CRP/ESR, and elevated D-dimer.
- Biomarkers like baseline IgE levels, inflammatory markers (CRP/ESR), autoimmune markers (ASST+, BAT/BHRA+), and cell counts (basopenia, eosinopenia) predict response to omalizumab and cyclosporine.
- Normal/elevated IgE and FceR1 overexpression may indicate faster omalizumab response.
Conclusions
- While several biomarkers show potential for predicting CSU treatment response, none are fully validated for routine clinical use.
- Large-scale prospective studies are essential to confirm these predictive biomarkers and discover new ones for personalized CSU medicine.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
